<DOC>
	<DOCNO>NCT02474589</DOCNO>
	<brief_summary>Multicenter , double-blind , placebo control , Phase 3 study determine safety tolerability oral tecovirimat , anti orthopoxvirus compound , subject .</brief_summary>
	<brief_title>A Trial Assess Safety , Tolerability , Pharmacokinetics Anti-Orthopoxvirus Compound Tecovirimat</brief_title>
	<detailed_description>Pharmacokinetics safety tolerability data collect .</detailed_description>
	<mesh_term>Smallpox</mesh_term>
	<criteria>18 80 year old , inclusive Available clinical followup duration study Able willing give inform consent In good general health without clinically significant medical history ; hospitalize chronic medical condition last 2 year Able comply dietary requirement throughout study drug dose period Adequate venous access individual participate PK test PE laboratory result without clinically significant finding within 14 day receipt study drug Agree drink alcohol begin Screening Period completion Day 28 Follow Visit Agree use nicotine product , include electronic vapor cigarette , nicotine patch nicotine gum least 30 day Day 1 Visit completion Day 15 Dosing complete Visit Agree consume caffeine study visit , include overnight stay participate PK subset Agree receive immunizations/vaccinations Agree take herbal product Able willing refrain take prescription nonprescription medication exception For woman childbearing potential , negative serum urine pregnancy test If male , agree donate sperm Meet 1 follow criterion : The subject partner undergone surgical sterilization ; subject postmenopausal ; subject agree abstinent ; subject agree consistently use method approve birth control . Pregnant breastfeed planning pregnancy Have history clinically significant condition Have limitation activity relate cardiac disease Have bleed disorder diagnose doctor , history significant bruising bleed intramuscular injection blood draw Currently use certain medication Have malignancy active treated malignancy reasonable assurance sustain cure , malignancy likely recur study Have history seizure Have clinically significant blood dyscrasia Have history drug allergy contraindicate participation trial Have medical , psychiatric , social condition occupational reason , responsibility judgment investigator would render subject unable comply protocol Have inability swallow medication Have clinically significant abnormal ECG Have participate clinical trial within 30 day study entry planning participate experimental treatment study study period Have history current drug alcohol abuse Have receive immunizations/vaccines Have current clinically significant acute bacterial , fungal , mycobacterial infection require administration systemic antibiotic Have know chronic bacterial , mycobacterial , fungal , parasitic , protozoal infection exception clinically significant dermal infection Have know hepatitis B C infection , positive test result Have know HIV infection AIDS positive test HIV Have current clinically significant viral infection Have know clinically significant chronic viral infection receive treatment great 20 mg prednisone equivalent dose immunosuppressant immunomodulary medication Have abnormal laboratory test screen Have great equal 20 % risk suffer major cardiovascular event Have previously enrol clinical trial involve tecovirimat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Treatment</keyword>
	<keyword>orthopoxvirus</keyword>
	<keyword>smallpox</keyword>
</DOC>